Paclitaxel and cisplatin promote miR-522 secretion from cancer-associated fibroblasts by activating USP7/hnRNPA1 axis, leading to arachidonate lipoxygenase 15 suppression and decreased lipid-ROS accumulation in cancer cells and ultimately promote acquired chemoresistance in gastric cancer (Zhang et al., 2020a). Here, ALOX15 is linked to cancer.